Search research articles
Contact Us
Filters
Showing results (161-170 of 293) with videos related to
Page
of 30
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 17, 2015
Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer
Joseph A Sparano, Fengmin Zhao, Silvana Martino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2015
Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial)
Marta Epeldegui, Jeannette Y Lee, Anna C Martínez, et al.
Journal of Oncology Practice
|
September 12, 2013
Do community-based patient assistance programs affect the treatment and well-being of patients with breast cancer?
Nina A Bickell, Andrea N Geduld, Kathie-Ann Joseph, et al.
Cancer
|
April 1, 2021
Breast cancer patients' insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOG-ACRIN TAILORx trial
Gelareh Sadigh, Robert J Gray, Joseph A Sparano, et al.
Cancer
|
June 22, 2010
Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy
Mary Cianfrocca, Sandra Lee, Jamie Von Roenn, et al.
Cancers
|
April 5, 2020
Validation of an Automated Quantitative Digital Pathology Approach for Scoring TMEM, a Prognostic Biomarker for Metastasis
David Entenberg, Maja H Oktay, Timothy D'Alfonso, et al.
Breast Cancer Research and Treatment
|
March 4, 2014
Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103
Kathryn J Ruddy, Anne O'Neill, Kathy D Miller, et al.
Cancer Chemotherapy and Pharmacology
|
February 15, 2020
Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up
Bhavana Pothuri, Allison L Brodsky, Joseph A Sparano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 17, 2012
Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma
Adam M Petrich, Violetta Leshchenko, Pei-Yu Kuo, et al.
JCO Precision Oncology
|
January 16, 2018
Impact of Genetic Ancestry on Outcomes in ECOG-ACRIN-E5103
Bryan P Schneider, Fei Shen, Guanglong Jiang, et al.
Page
of 30
Search research articles
Search
Showing results (161-170 of 293) with videos related to
Sort By:
Page
of 30
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 17, 2015
Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer
Joseph A Sparano, Fengmin Zhao, Silvana Martino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2015
Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial)
Marta Epeldegui, Jeannette Y Lee, Anna C Martínez, et al.
Journal of Oncology Practice
|
September 12, 2013
Do community-based patient assistance programs affect the treatment and well-being of patients with breast cancer?
Nina A Bickell, Andrea N Geduld, Kathie-Ann Joseph, et al.
Cancer
|
April 1, 2021
Breast cancer patients' insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOG-ACRIN TAILORx trial
Gelareh Sadigh, Robert J Gray, Joseph A Sparano, et al.
Cancer
|
June 22, 2010
Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy
Mary Cianfrocca, Sandra Lee, Jamie Von Roenn, et al.
Cancers
|
April 5, 2020
Validation of an Automated Quantitative Digital Pathology Approach for Scoring TMEM, a Prognostic Biomarker for Metastasis
David Entenberg, Maja H Oktay, Timothy D'Alfonso, et al.
Breast Cancer Research and Treatment
|
March 4, 2014
Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103
Kathryn J Ruddy, Anne O'Neill, Kathy D Miller, et al.
Cancer Chemotherapy and Pharmacology
|
February 15, 2020
Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up
Bhavana Pothuri, Allison L Brodsky, Joseph A Sparano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 17, 2012
Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma
Adam M Petrich, Violetta Leshchenko, Pei-Yu Kuo, et al.
JCO Precision Oncology
|
January 16, 2018
Impact of Genetic Ancestry on Outcomes in ECOG-ACRIN-E5103
Bryan P Schneider, Fei Shen, Guanglong Jiang, et al.
Page
of 30